21/01/2026
A pilot registry study found that treatment with an oral gotu kola extract (Centella asiatica) significantly improved the closure and healing rates of chronic venous leg ulcers when used in addition to best management treatment.
The study included 160 patients with venous ulcers and chronic venous insufficiency (CVI). One group received 675 mg/day of oral gotu kola extract (standardised to 35% total triterpenes) along with best management (BM) practices (compression, elevation, wound cleaning), while a control group received only BM.
The results demonstrated a significant improvement in the herbal group:
• Ulcer Closure Rate: 96.2% of ulcers in the gotu kola group achieved complete closure after 90 days, compared to 83.7% in the control group.
• Faster Healing: after just one month, 65% of ulcers in the gotu kola group were completely healed, versus only 18.75% in the control group.
• Reduced Ulcer Area: the average ulcer area in the gotu kola group decreased dramatically (from 2.34 cm² to 0.33 cm²), a significantly greater reduction than that observed in the control group (from 2.4 cm² to 1.61 cm²).
• Improved Microcirculation: the herbal group showed enhanced microcirculatory parameters, including improved skin resting flux and transcutaneous oxygen/carbon dioxide partial pressures, indicating better blood flow and tissue oxygenation.
Gotu kola remains our leading herb for tissue repair and microvascular support, and this trial further vindicates its clinical value. Notably, the dose used was high, but still realistic and achievable in practice. The benefits observed in this venous ulcer study are well explained by its established pharmacology. The triterpenes asiaticoside and madecassoside improve microcirculation and venous tone, helping reduce venous hypertension and local tissue hypoxia—central drivers of ulcer chronicity. At the same time, the herb promotes healing through enhanced fibroblast activity, collagen synthesis, and extracellular matrix repair, accelerating granulation and re-epithelialisation. Its anti-inflammatory effects temper chronic wound inflammation, while modulation of transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF) signalling supports angiogenesis and tissue remodelling.
For more information see: https://pubmed.ncbi.nlm.nih.gov/40719428/
